GALT Joel Lewis sells $50K worth of shares
Dec 27, 2024, 5:33 AM
-5.43%
What does GALT do
Galectin Therapeutics, based in Norcross, Georgia, focuses on developing therapies for fibrotic diseases, severe skin diseases, and cancer, with its lead drug, belapectin, targeting galectin-3. The company, with 14 employees, has programs for metabolic dysfunction-associated steatohepatitis and advanced cancers.
Joel Lewis sold 56,000 shares of GALT on 23 December at $0.89 per share, worth a total of $50K. They now own 897,012 GALT shares, or a 6% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.